Product Name: Cytokeratin 10 Antibody [SPM623]
Species Reactivity: Cat, Dog, Human
Tested Applications: Flow, IF, IHC-P
Applications: Flow Cytometry: 0.5-1 ug/million cells in 0.1mlImmunofluorescence: 0.5-1 ug/mlImmunohistochemistry (FFPE): 0.1-0.2 ug/ml for 30 min at RTOptimal dilution of the Cytokeratin 10 antibody should be determined by the researcher.
User Note: Optimal dilutions for each application to be determined by the researcher
Predicted Molecular Weight:
Immunogen: A cytoskeletal preparation extracted from human ectocervical epithelium was used as the immunogen for the Cytokeratin 10 antibody.
Host Species: Mouse
Purification: Protein G affinity chromatography
Physical State: Liquid
CAS NO.: 480449-71-6
Product: Edoxaban (tosylate)
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Conditions: Aliquot and Store at -20C. Avoid freez-thaw cycles.
Clonality: Monoclonal
Conjugate: Unconjugated
Alternate Names: Keratin, type I cytoskeletal 10, Cytokeratin-10, CK-10, Keratin-10, K10, KRT10, KPP
Accession NO.:
Protein Ino:
Official Symbol: KRT10
Geneid: 3858
Background: This mAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.
PubMed ID:http://aac.asm.org/content/37/12/2684.abstract
